Compare Invesco DB Agriculture Fund (DBA) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs GSK plc — how do they compare? Invesco DB Agriculture Fund trades at $28.43 (market cap $1.32B), while GSK plc trades at $46.47 (market cap $91.88B). The key difference: GSK plc is far larger — about 69.6× Invesco DB Agriculture Fund's market cap, and GSK plc pays a 3.9% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and GSK plc for 93 Days on average.
| DBA | GSK | |
|---|---|---|
Market Cap | $1.32B | $91.88B |
Volume | 771,657 | 7,730,529 |
52-Week High | $29.49 | $61.18 |
52-Week Low | $25.44 | $43.24 |
Typical Hold Time | 24 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.42, down 0.25% on the day, with a bearish technical signal from moving averages but neutral oscillators. The fund has returned 12.4% year-to-date, closely tracking the S&P 500, supported by agricultural commodity strength from weather risks and geopolitical tensions. Recent news highlights DBA's consolidation near all-time highs with a 3.25% yield, though it faces a high expense ratio of 0.85%.
Outlook remains mixed with bullish agricultural trends from El Niño and demand catalysts balanced by sector volatility and expense concerns. Key risks include commodity price swings and geopolitical developments, while institutional sentiment leans neutral with a Hold rating from analysts citing momentum versus cost trade-offs.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
